No profile data available.
Maia Biotechnology, Inc. (MAIA) is a healthcare company in the additional cancer treatment drugs industry, based in Chicago, United States, with about 13 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$22.40 million. Its market capitalization was $75.33 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Maia Biotechnology reported $0 in revenue for fiscal year 2025.
$75.33 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Sutro Biopharma, Inc. (STRO), Instil Bio, Inc. (TIL), OS Therapies Incorporated (OSTX), Oncolytics Biotech Inc. (ONCY).